Author:
H Riordan Neil,Gerardo Jiménez Arias Luis,Coronado Ramón
Abstract
Numerous and diverse participants are involved in the development of novel therapies: patients, physicians, scientists, sponsors, governing bodies, lawmakers, institutional review boards, and bioethics proponents. While the welfare of the patient must always and unquestionably be at the forefront of any intervention along with informed consent, their wishes, their requests, and their expectations should also be considered at every step. The availability of stem cell research in various countries with dissimilar regulatory agencies has opened the door for thought-provoking questions about their validity from an ethical, legal, and moral perspective, which will be addressed in this chapter, framed within the doctor-patient relationship.
Reference91 articles.
1. Ichim TE, Solano F, Lara F, Paris E, Ugalde F, Rodriguez JP, et al. Feasibility of combination allogeneic stem cell therapy for spinal cord injury: A case report. International Archives of Medicine. 2010;3:30
2. Organization of American States, editor. American Declaration of the Rights and Duties of Man. Bogotá: Ninth International Conference of American States; 1948
3. Executive Power of Costa Rica. Decreto Ejecutivo N° 39986-S: Autorización para las Terapias Regenerativas con Células Madre Adultas. San José, Costa Rica: La Gaceta Costa Rica; 2016
4. Falit BP, Gross CP. Access to experimental drugs for terminally ill patients. Journal of the American Medical Association. 2008;300(23):2793-2795
5. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiation Research. 1961;14(2):213-222
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献